A
ACAD
ACADIA Pharmaceuticals Inc. Common Stock
$19.25
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of ACADIA Pharmaceuticals Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
$2.21
P/E
8.9
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: $0.20
Nov 11
Posts
No posts about ACAD yet.
About ACADIA Pharmaceuticals Inc. Common Stock
ACADIA Pharmaceuticals is a US biotechnology company that develops drugs for brain and nervous system conditions. It makes money mainly by selling Nuplazid, a treatment for hallucinations and delusions linked to Parkinson's disease, and Daybue, the first approved treatment for Rett syndrome, a rare genetic disorder that affects children. It also spends heavily on research to build its next generation of drugs.